Rociverine
Top View
- Customs Tariff - Schedule
- Transdermal Device Containing
- NVA237 / Glycopyrronium Bromide Multinational, Multi-Database Cohort
- Efficacy of Soluble Fibre, Antispasmodic Drugs, and Gut–Brain Neuromodulators in Irritable Bowel Syndrome: a Systematic Review and Network Meta-Analysis
- Irritable Bowel Syndrome: Full Guideline Draft (August 2007) DRAFT for CONSULTATION
- Customs Tariff - Schedule Xxi - 1
- Oil in the Treatment of Irritable Bowel Effect of Fibre, Antispasmodics, And
- IBS-Monograph-2018.Pdf
- Effect of Fibre, Antispasmodics, and Peppermint Oil in the Treatment of Irritable Bowel Syndrome: Systematic Review and Meta-Analysis
- (12) United States Patent (10) Patent No.: US 9.474,719 B2 Mullen Et Al
- The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
- Non-Interventional Study Protocol
- Non-Interventional Study Protocol NVA237A2401T
- The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
- [Ehdsi V3.0.0-RC1] Ehealth DSI – Master Value Set Catalogue
- Pharmaceutical Appendix to the Tariff Schedule 2
- American College of Gastroenterology Monograph on the Management of Irritable Bowel Syndrome and Chronic Idiopathic Constipation
- QVA149 / Indacaterol / Glycopyrronium Bromide